Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

Bristol Myers yields 4.4%, has a 72% payout ratio and 17 consecutive years of dividend increases, but is at risk from patent cliffs on key drugs (Eliquis, Opdivo). Revenue was flat at $48.2B last year and the company guides $46.0–$47.5B for the current year, signaling potential top-line pressure; generic competition and possible acquisition responses could reduce cash available for dividends. The article advises against treating BMY as a buy-and-forget income stock and recommends dividend-paying index funds as a safer alternative.

Analysis

Patent expirations are not just an earnings problem for the company; they force a strategic reset that cascades into pricing, salesforce allocation, and capital allocation. Expect near-term margin pressure in legacy franchises to increase promotional discounts and tendering activity, which will mechanically reduce free cash flow available for shareholder returns and make buybacks less likely even if headline payouts persist.

M&A and bolt-on deals are the natural corporate response to branded revenue erosion, but they shift risks from market execution to integration and leverage. A large acquisition within 6–24 months would likely compress credit metrics, widen credit spreads for the issuer, and create a transient opportunity to short the acquirer's stock or long credit protection if deal financing is aggressive.

Key catalysts to watch on a 3–18 month timetable are biosimilar approvals and settlement announcements, late-stage readouts for the company’s next-wave programs, and any unexpected divestiture or deal activity; each will reprice both equity and implied volatility rapidly. The path to reversing downward momentum is binary — favorable trial outcomes or favorable litigation settlements can restore pricing power, whereas accelerated generic penetration will produce multi-quarter operating deficits.

A pragmatic trading mindset is asymmetry — protect downside while leaving a small sleeve for upside optionality tied to positive clinical or legal outcomes. Use defined-risk options to express views, and consider cross-asset hedges (equity vs. sector ETF or credit) to isolate idiosyncratic patent/legal risk from broader healthcare beta.

Key Decisions for Investors

• Pair trade (6–12 months): Short the company (size 0.5–1.0% NAV) vs long a diversified healthcare ETF (XLV) of equal notional to hedge sector beta. Target: 20–30% relative downside in the company if biosimilars accelerate; stop-loss: cut after 10% relative adverse move or a clear favorable legal/clinical outcome.
• Defined-risk put spread (12–18 months): Buy a 12–18 month put spread on the company sized to 1% NAV with protection starting ~20% below spot to ~40% below spot (pay ~1–3% of notional). Rationale: limited premium for >20% downside protection vs outright short; roll or unwind if biosimilar approvals are delayed beyond 18 months.
• Event call spread (6–12 months): Buy a 6–12 month call spread on the company sized to 0.25–0.5% NAV to capture upside from a positive late-stage readout or favorable litigation settlement. Risk/reward: pay small premium for asymmetric upside (target 2–4x payoff if catalyst is positive), cap losses to premium paid.
• Volatility harvest after sell-off (3–9 months): If the stock gaps down >15% on biosimilar news, consider selling 6–9 month OTM put credit spreads (20%+ OTM) to collect yield against buying the dip, or sell implied vol (strangles) sized to 0.5% NAV only after implied volatility spikes and before litigation/clinical deadlines. Risk: large binary losses if multiple negative catalysts hit; hard stop if underlying falls an additional 15%.